Prenatal screening for Down syndrome in England and Wales and population-based birth outcomes

American Journal of Obstetrics and Gynecology

Volumn 189, Issue 4, 2003, Pages 980-985

  Smith Bindman, Rebecca ^a   Chu, Philip ^a   Bacchetti, Peter ^a   Waters, Jonathan J ^b   Mutton, David ^c   Alberman, Eva ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Birth outcome; Down syndrome; Prenatal screening; Serum biochemistry; Ultrasound examination

Indexed keywords

ADULT; AMNIOCENTESIS; ARTICLE; BLOOD CHEMISTRY; CHORION VILLUS SAMPLING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DOWN SYNDROME; FEMALE; FETUS; FETUS ECHOGRAPHY; FETUS OUTCOME; HUMAN; INTERMETHOD COMPARISON; KARYOTYPING; MAJOR CLINICAL STUDY; MATERNAL AGE; POPULATION RESEARCH; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0242425764     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0002-9378(03)00721-X     Document Type: Article

References (30)

1. Rhoads GG, Jackson LG, Schlesselman SE, de la Cruz FF, Desnick RJ, Golbus MS, et al. The safety and efficacy of chorionic villus sampling for early prenatal diagnosis of cytogenetic abnormalities. N Engl J Med 1989;320:609-17.
2. Midtrimester amniocentesis for prenatal diagnosis: safety and accuracy. JAMA 1976;236:1471-6.
3. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986;1:1287-93.
4. Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis: the Canadian Early and Mid-trimester Amniocentesis Trial (CEMAT) Group. Lancet 1998;351:242-7.
5. Ventura S, Martin J, Curtin S, Mathews T, Park M. Births: final data for 1998 national vital statistics reports. Hyattsville (Md): National Center for Health Statistics; 1998.
6. Adams M, Erickson J, Layde P. Down's syndrome: recent trends in the United States. JAMA 1981:758-60.
7. Egan JF, Benn P, Borgida AF, Rodis JF, Campbell WA, Vintzileos AM. Efficacy of screening for fetal Down syndrome in the United States from 1974 to 1997. Obstet Gynecol 2000;96:979-85.
8. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997;4:181-246.
9. Haddow JE, Palomaki GE, Knight GJ, Canick JA, Saller DN Jr, Panizza DS. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992;327:588-93.
10. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multi-centre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation: Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;352:343-6.
11. Schuchter K, Hafner E, Stangl G, Ogris E, Philipp K. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population. Ultrasound Obstet Gynecol 2001;18:23-5.
12. Hafner E, Schuchter K, Philipp K. Screening for chromosomal abnormalities in an unselected population by fetal nuchal translucency. Ultrasound Obstet Gynecol 1995;6:330-3.
13. Cuckle H. Integrating antenatal Down's syndrome screening. CurrOpin Obstet Gynecol 2001;13:175-81.
14. Palomaki GE, Knight GJ, McCarthy JE, Haddow JE, Donhowe JM. Maternal serum screening for Down syndrome in the United States: a 1995 survey. Am J Obstet Gynecol 1997;176:1046-51.
15. Wald NJ, Huttly WJ, Hennessy CF. Down's syndrome screening in the UK in 1998 [letter]. Lancet 1999;354:1264.
16. Wellesley D, Boyle T, Barber J, Howe D. Retrospective audit of different antenatal screening policies for Down's syndrome in eight district general hospitals in one health region. BMJ 2002;325:15-7.
17. Cheffins T, Chan A, Haan EA, Ranieri E, Ryall RG, Keane RJ, et al. The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia. BJOG 2000;107:1453-9.
18. Palomaki G, Haddow J, Beauregard L. Prenatal screening for Down's syndrome in Maine, 1980-1993. N Engl J Med 1996;334:1409-10.
19. Smith NC, Hau C. A six year study of the antenatal detection of fetal abnormality in six Scottish health boards. BJOG 1999;106:206-12.
20. Verloes A, Gillerot Y, Van Maldergem L, Schoss R, Herens C, Jamar M, et al. Major decrease in the incidence of trisomy 21 at birth in south Belgium: Mass impact of triple test? Eur J Hum Genet 2001;9:1-4.
21. The California Expanded AFP Screening Program: prenatal care provider handbook. Berkeley (CA): California Department of Health Services, Genetic Disease Branch; 1997
22. Jorgensen FS, Valentin L, Salvesen KA, Jorgensen C, Jensen FR, Bang J, et al. MULTISCAN: a Scandinavian multi-center second trimester obstetric ultrasound and serum screening study. Acta Obstet Gynecol Scan 1999;78:501-10.
23. Alberman E. The National Down Syndrome Cytogenetic Register. J Med Screen 2002;9:97-8.
24. Waters J, Waters K. Trends in cytogenetic prenatal diagnosis in the UK: results from UK NEQAS external audit. Prenat Diagn 1999;19:1023-6.
25. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999;341:461-7.
26. Cunningham GC, Tompkinison DG. Cost and effectiveness of the California triple marker prenatal screening program. Genet Med 1999;1:199-206.
27. American College of Medical Genetics Clinical Practice Committee. ACMG position statement on multiple marker screening in women 35 and older. American College of Medical Genetics Newsletter 1994;2.
28. American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists: prenatal diagnosis of fetal chromosomal abnormalities. Obstet Gynecol 2001;97(suppl):1-12.
29. US Department of Health and Human Services, Office of Public Health and Science, Office of Disease Prevention and Health Promotion. Guide to clinical preventive services: report of the US Preventive Services Task Force. Washington (DC): US Government Printing Office; 1996.
30. American College of Obstetricians and Gynecologists. Down Syndrome Screening. Washington (DC): The College; 1994. Committee Opinion No.: 141.